Daratumumab has been used to treat over 484,000 patients globally since its launch. In Ireland, Darzalex in combination with lenalidomide and dexamethasone has been reimbursed for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplant. The Phase 3 MAIA study showed that the combination regimen reduced the risk of disease progression or death by 44 percent in these patients. The study also demonstrated improved progression-free survival and deeper responses with the addition of daratumumab. This new treatment option provides hope for Irish patients with limited therapeutic options for multiple myeloma.
Source link
Darzalex▼ (daratumumab) approved in Ireland for reimbursement for multiple myeloma patients
